Enclomiphene Citrate Cost in Alaska 2026: Cash Pay, Compounded, and Coverage Guide

What Enclomiphene Citrate Is and Why Men Use It

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It binds estrogen receptors in the hypothalamus and pituitary, reducing negative feedback and raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The result is increased intratesticular testosterone production without suppressing sperm output, which separates it mechanistically from exogenous testosterone replacement therapy. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and sharply reduces sperm counts, a side effect men hoping to preserve fertility want to avoid.

Kim et al. (BJU Int, 2016, N=124) compared enclomiphene to topical testosterone in men with secondary hypogonadism. At 16 weeks, enclomiphene 12.5 mg daily restored serum testosterone to normal range in 75.7% of participants while maintaining sperm concentrations above baseline, versus a decline in the testosterone-gel group. That trial remains the most-cited head-to-head comparison in the literature and anchors most prescriber rationale for choosing enclomiphene over TRT in fertility-concerned patients.

The FDA approved enclomiphene citrate under the brand name Androxal (NDA 022134) specifically for secondary hypogonadism in adult men. The full prescribing information and approval letter are publicly available through the FDA's drug database. Because hypogonadism is the approved indication, prescribing for that diagnosis is on-label; prescribing for other purposes, such as post-cycle therapy in athletes, is off-label.

Secondary hypogonadism affects an estimated 2.1% to 5.7% of adult men in the United States, with prevalence rising with age and body mass index. Population-level data from NHANES waves analyzed by Mulligan et al. found that 38.7% of obese men had low testosterone, compared with 12.8% of normal-weight men. Alaska's demographics, including a high proportion of working-age men in physically demanding industries and documented rates of obesity in rural communities, make the condition clinically relevant across the state.

Enclomiphene Citrate Cash-Pay Price in Alaska

The practical cash-pay price for most Alaskan patients in 2026 is approximately $90 per month through a licensed 503A compounding pharmacy. That figure reflects compounded oral capsules or tablets at 12.5 mg to 25 mg per day, dispensed in a 30-day supply. No major retail chain currently stocks a commercially manufactured generic at that price point; brand Androxal, where available, carries a significantly higher list price that most cash-paying patients cannot absorb without insurance.

Alaska has no price-control statute that caps what a pharmacy may charge for a compounded preparation. The Alaska Board of Pharmacy licenses and inspects compounding pharmacies under Alaska Statute 08.80 and the relevant provisions of federal DQSA (Drug Quality and Security Act) requirements. A 503A pharmacy compounds for individual patients based on a valid prescription; it does not manufacture in bulk for general distribution, which is the 503B outsourcing-facility model.

Shipping from a lower-48 503A pharmacy to an Alaska address is legal provided the pharmacy holds an active Alaska non-resident pharmacy permit. Many telehealth-linked compounding pharmacies do ship to Alaska, though patients in extremely remote zip codes may face two-to-three-day transit times that affect temperature-sensitive formulations.

Cost varies by dose. At 12.5 mg daily, a 30-day supply of compounded capsules sits near the $90 floor. Doubling to 25 mg daily may add $20 to $40 depending on the pharmacy, because capsule fill weight and base-material costs scale roughly linearly. The FDA has published guidance on what 503A pharmacies may and may not do, including prohibition on making copies of commercially available drugs without a clinical need documented in the prescription.

Patients comparing prices should request an itemized quote, not just the dispensing fee. Some pharmacies quote a low capsule price but charge separately for the consultation, lab requisition, and shipping. For a patient in Anchorage or Fairbanks with access to a local lab, splitting those services across a telehealth prescriber and a local draw site may reduce the monthly total.

Is Compounded Enclomiphene Citrate Legal in Alaska?

Yes. Compounded enclomiphene citrate is legal in Alaska when dispensed by a 503A-licensed pharmacy on the basis of a valid, patient-specific prescription from a licensed prescriber. The key legal framework is the federal Drug Quality and Security Act of 2013, which amended Section 503A of the Federal Food, Drug, and Cosmetic Act. That statute defines what a compounding pharmacy must do to remain outside FDA's new-drug-application requirements while still producing patient-specific preparations.

Alaska does not maintain a separate state-level prohibition on compounded enclomiphene. The Alaska Board of Pharmacy's regulations for non-sterile compounding align with USP Chapter 795 standards. As long as the prescriber is licensed in Alaska (or holds a valid telehealth prescribing authorization under Alaska's telehealth statutes), and the pharmacy holds the required permits, the transaction is fully compliant.

One caveat: the FDA has at times issued guidance suggesting that compounding a copy of a commercially available, FDA-approved drug requires a documented clinical reason. Because brand Androxal exists as an approved product, the prescribing clinician's chart note should specify why a compounded formulation is clinically appropriate for that individual patient, such as cost barrier, unavailability of the brand at local pharmacies, or need for a non-standard dose. FDA's 2018 draft guidance on what constitutes a "copy" of an approved drug is publicly available.

The practical compliance framework for an Alaskan patient: (1) obtain a prescription from a licensed prescriber who documents the clinical rationale; (2) confirm the compounding pharmacy holds an Alaska non-resident permit if it is based outside the state; (3) confirm the pharmacy operates under USP 795 for non-sterile oral compounding; (4) verify that the active pharmaceutical ingredient (enclomiphene citrate) is sourced from an FDA-registered facility. That four-step check covers the main regulatory bases.

Alaska Medicaid Coverage for Enclomiphene Citrate

Alaska Medicaid does not cover enclomiphene citrate for secondary hypogonadism in adult men as of 2026. The Alaska Division of Health Care Services administers Medicaid pharmacy benefits under the Alaska Medicaid Pharmacy Program, which uses a preferred drug list and prior-authorization system. Enclomiphene does not appear on the preferred drug list, and no prior-authorization pathway has been established for this indication.

The Alaska Medicaid Pharmacy Program's preferred drug list and coverage policies are publicly searchable through the Alaska Department of Health. Clinicians who believe a patient has a compelling medical need may submit a prior-authorization request, but approval for an off-label, non-listed agent is unlikely without a documented failure of covered alternatives.

Testosterone replacement therapy products, such as testosterone cypionate and certain topical gels, do appear on some state Medicaid formularies when prescribed for hypogonadism. For a Medicaid-insured patient who cannot afford compounded enclomiphene at cash-pay rates, a conversation with the prescriber about covered alternatives is worth having, with the caveat that injectable testosterone suppresses spermatogenesis in a way enclomiphene does not.

Patients enrolled in Alaska's Denali KidCare or other children's health programs are not a relevant population for this drug, which is approved only for adult men.

Commercial Insurance Coverage in Alaska

Commercial insurance coverage for enclomiphene citrate in Alaska is rare and inconsistent. Most major payers, including Premera Blue Cross Blue Shield of Alaska and Moda Health (which are the dominant commercial carriers in the state), do not include enclomiphene on standard formularies. Some plans with a specialty-drug tier may consider prior-authorization requests, but approval typically requires documented low serum testosterone on two morning measurements, documentation of secondary rather than primary hypogonadism, and failure of or contraindication to a preferred formulary agent.

The Endocrine Society's clinical practice guideline on male hypogonadism recommends confirming the diagnosis with two morning total testosterone measurements below the laboratory's lower reference limit before initiating therapy. Meeting that documentation standard before submitting a prior-authorization request materially improves approval odds.

Even when a plan covers the brand product, the patient's cost-share at specialty-tier pricing can exceed $200 per month, making compounded enclomiphene at $90 per month the more affordable path even for insured patients. Some telehealth clinics provide a letter of medical necessity template that patients can submit to their insurer alongside a formal appeal if an initial claim is denied.

Federal Employee Health Benefit (FEHB) plans covering Alaska federal workers, including many stationed at military installations, vary by plan option. The GEHA Standard and High Options, for example, have different specialty-drug tiers. Federal employees should call the plan's pharmacy benefit line with the NDC for Androxal before assuming coverage.

Telehealth Access to Enclomiphene in Alaska

Telehealth prescribing of enclomiphene citrate is legal throughout Alaska. Alaska Senate Bill 241, enacted in 2020 and subsequently extended, created a durable framework for telehealth prescribing that does not require an in-person visit before a provider issues a prescription, provided the prescriber can establish a valid patient-provider relationship via synchronous audio-video. Alaska's telehealth statutes are codified under Alaska Statute 47.05.270.

For men in Anchorage, Fairbanks, Juneau, or the Matanuska-Susitna Valley, a telehealth appointment followed by a local lab draw (LabCorp and Quest both operate collection sites in these cities) covers the clinical workflow without any travel. For men in bush communities accessible only by small aircraft, a telehealth visit followed by a mail-in dried blood spot testosterone assay or a draw at a local Indian Health Service clinic can substitute for a commercial lab.

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency supports measuring total testosterone, LH, and FSH in the initial workup to confirm secondary rather than primary hypogonadism. That workup is achievable entirely through telehealth and remote lab services for most Alaskan men.

A standard telehealth workflow for enclomiphene in Alaska runs roughly as follows. The patient books a video visit, typically 20 to 30 minutes. The prescriber reviews symptom history, orders labs if not already completed, and reviews results at a follow-up appointment. A prescription is sent electronically to the patient's chosen pharmacy. Follow-up lab checks, commonly at 6 to 8 weeks to assess testosterone, LH, and FSH response, can be ordered remotely and drawn locally. Studies on enclomiphene pharmacodynamics show measurable LH and FSH elevation within the first two weeks of daily dosing, so early lab confirmation of response is clinically meaningful.

How 503A Compounded Savings and Discount Programs Work in Alaska

No manufacturer coupon exists for compounded enclomiphene the way GoodRx or a manufacturer's savings card might apply to a brand-name drug. Because 503A compounds are patient-specific preparations rather than manufactured drugs, they do not carry NDCs eligible for standard copay-card processing through pharmacy benefit managers.

What patients can access includes the following options. GoodRx and similar discount platforms do not apply to most 503A compounded preparations, but they do apply to commercially available clomiphene citrate (the racemate), which some prescribers use off-label as an enclomiphene alternative. Clomiphene citrate 25 mg to 50 mg daily has been studied for secondary hypogonadism and raises testosterone, though it also raises estradiol more than the pure enclomiphene isomer does, which can cause gynecomastia at higher doses.

Some telehealth platforms offer bundled subscription pricing that includes the prescriber consultation, lab-order fee, and pharmacy coordination in a flat monthly rate. When that bundle price undercuts the sum of individual service costs, it represents a real saving. Patients should compare the all-in monthly cost, including labs, before selecting a platform.

Manufacturer patient-assistance programs do not currently apply to compounded enclomiphene. If brand Androxal becomes more widely distributed and a patient assistance program is established, it would apply only to the brand product dispensed at a retail pharmacy, not to the compounded version.

The FDA's 340B drug pricing program applies to certain covered entities serving low-income populations, including some Alaska Native health corporations and federally qualified health centers. Patients receiving care through an Alaska Native health system should ask the clinic pharmacist whether any testosterone-axis medications are accessible under 340B pricing.

Expected Lab and Monitoring Costs in Alaska

The drug cost is only part of the monthly spend. Monitoring labs add to the total. A baseline male hormone panel (total testosterone, free testosterone, LH, FSH, estradiol, complete blood count, and comprehensive metabolic panel) at a LabCorp or Quest site in Anchorage runs roughly $120 to $250 cash-pay without insurance. Reference ranges and clinical thresholds for these markers are detailed in the Endocrine Society's 2018 guideline on male hypogonadism.

Follow-up panels at 6 to 8 weeks and then every 3 to 6 months once stable typically include total testosterone, LH, FSH, and estradiol, a narrower draw costing $60 to $120 cash-pay. Some telehealth platforms negotiate discounted lab rates for their patient panels; asking upfront whether the platform has a lab partnership in Alaska can materially lower this line item.

For patients with commercial insurance, labs may be covered under the preventive or diagnostic benefit, depending on how the prescriber codes the visit. Secondary hypogonadism (ICD-10 E29.1) is a covered diagnosis for lab work under most major medical plans, even when the drug itself is not covered on the pharmacy benefit.

Comparing Enclomiphene to Covered Alternatives in Alaska

Because neither Alaska Medicaid nor most commercial plans cover enclomiphene, comparing its total cost to covered alternatives helps patients make informed decisions.

Injectable testosterone cypionate 200 mg/mL is generically available and covered on most formularies, including Alaska Medicaid, for confirmed hypogonadism. Cash-pay price at most Alaska pharmacies runs $30 to $60 for a 10 mL vial lasting roughly 10 weeks at 100 mg per week. That $3 to $6 per week cost is lower than enclomiphene, but testosterone injections suppress LH and FSH to near-zero, making them incompatible with fertility preservation goals.

Clomiphene citrate (the racemate, not the purified trans-isomer) is available as a generic, costs roughly $15 to $40 per month cash-pay with a GoodRx coupon at Alaska pharmacies, and is sometimes prescribed off-label for hypogonadism. A 2013 study (N=86) by Krzastek et al. showed clomiphene citrate 25 mg every other day raised total testosterone from a mean of 232 ng/dL to 612 ng/dL over 12 months, with 64% of men achieving normal testosterone levels. The trade-off is higher estradiol elevation compared with purified enclomiphene, because the cis-isomer (zuclomiphene) within clomiphene has estrogenic activity.

Anastrozole, an aromatase inhibitor, is sometimes added or used alone in men with secondary hypogonadism driven by excess aromatization; it costs $10 to $30 per month as a generic. However, anastrozole does not raise LH or FSH and works through a different mechanism. It is not a substitute for enclomiphene when the goal is increasing endogenous testosterone production.

The $90/month compounded enclomiphene cost makes the most clinical and financial sense for men who have documented secondary hypogonadism, are seeking fertility preservation, cannot tolerate the estradiol elevation from clomiphene racemate, and do not have insurance covering any of the options.

Practical Steps for an Alaskan Patient Starting Enclomiphene

Getting enclomiphene in Alaska in 2026 follows a repeatable sequence. First, confirm lab eligibility: two morning total testosterone measurements below 300 ng/dL, with LH and FSH in the normal or low range (confirming the secondary rather than primary pattern). The Endocrine Society guideline specifies morning draws before 10 a.m. because testosterone follows a diurnal rhythm with peak levels in the early morning hours.

Second, book a telehealth visit with a prescriber licensed in Alaska. Ask specifically whether the prescriber can send a prescription to a 503A compounding pharmacy and whether the platform has an Alaska-permitted pharmacy partner.

Third, confirm the pharmacy's Alaska non-resident permit number before paying. The Alaska Board of Pharmacy maintains a public license lookup tool. A 30-second search confirms the pharmacy's standing.

Fourth, set a calendar reminder for a 6-week follow-up lab draw. Kim et al. (2016) showed that testosterone normalization with enclomiphene occurs within 8 weeks in the majority of responders, so an 8-week check is the standard clinical interval to confirm the drug is working and to adjust dose if needed.

At 12.5 mg daily with a confirmed response at 8 weeks, the prescriber may hold that dose or titrate to 25 mg if testosterone remains below mid-normal range. Most patients do not require doses above 25 mg daily; the FDA-approved prescribing information for Androxal specifies 12.5 mg and 25 mg as the studied dose levels.